| 6.23 -0.17 (-2.66%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.99 | 1-year : | 8.97 |
| Resists | First : | 6.84 | Second : | 7.67 |
| Pivot price | 6.76 |
|||
| Supports | First : | 5.5 | Second : | 4.58 |
| MAs | MA(5) : | 6.19 |
MA(20) : | 6.76 |
| MA(100) : | 5.86  |
MA(250) : | 4.59 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 35.6 |
D(3) : | 33.9 |
| RSI | RSI(14): 44.4 |
|||
| 52-week | High : | 7.67 | Low : | 2.57 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PBYI ] has closed above bottom band by 24.5%. Bollinger Bands are 128% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.38 - 6.42 | 6.42 - 6.44 |
| Low: | 6.06 - 6.11 | 6.11 - 6.14 |
| Close: | 6.17 - 6.23 | 6.23 - 6.29 |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Mon, 02 Mar 2026
PBYI: NERLYNX sales rise, alisertib progresses in trials, and profitability is maintained - TradingView
Mon, 02 Mar 2026
PBYI: NERLYNX revenue grows as alisertib advances in biomarker-driven cancer trials; profitability sustained - TradingView
Sat, 28 Feb 2026
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2025 Earnings Call Transcript - Insider Monkey
Sat, 28 Feb 2026
Puma Biotechnology (PBYI) Margin Resilience Tests Bearish Earnings Forecasts In FY 2025 Results - Sahm
Sat, 28 Feb 2026
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by Wall Street Zen - MarketBeat
Sat, 28 Feb 2026
PBYI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 15.3 (%) |
| Held by Institutions | 73.4 (%) |
| Shares Short | 3,480 (K) |
| Shares Short P.Month | 3,440 (K) |
| EPS | 0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.28 |
| Profit Margin | 17.4 % |
| Operating Margin | 17.5 % |
| Return on Assets (ttm) | 9.8 % |
| Return on Equity (ttm) | 39.6 % |
| Qtrly Rev. Growth | -32.5 % |
| Gross Profit (p.s.) | 3.23 |
| Sales Per Share | 4.2 |
| EBITDA (p.s.) | 0.88 |
| Qtrly Earnings Growth | -58.5 % |
| Operating Cash Flow | 43 (M) |
| Levered Free Cash Flow | 32 (M) |
| PE Ratio | 8.41 |
| PEG Ratio | 0 |
| Price to Book value | 2.72 |
| Price to Sales | 1.48 |
| Price to Cash Flow | 7.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|